Year archive

Ipsen — 2024 filings

All 91 regulatory filings released by Ipsen (IPN) in 2024, sourced directly from the official regulator.

91 Filings

2024 Period

2024 filings (91)

Filing	Released	Lang
Ipsen - Novembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-12-09	French
Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Declaration of Voting Results & Voting Rights Announcements	2024-12-09	English
Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Declaration of Voting Results & Voting Rights Announcements	2024-11-07	English
Ipsen - Octobre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-11-07	French
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance Earnings Release 9M 2024	2024-10-23	English
Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'année 2024 et revoit à la hausse ses prévisions pour l'exercice en cours Earnings Release 9M 2024	2024-10-23	French
Franchissement de seuil Major Shareholding Notification	2024-10-22	French
Ipsen - Septembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-10-09	French
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Declaration of Voting Results & Voting Rights Announcements	2024-10-09	English
Franchissement de seuil Major Shareholding Notification	2024-09-23	French
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors Earnings Release Q3 2024	2024-09-16	English
Les résultats finaux de l’essai de Phase III CABINET corroborent les bénéfices en termes d’efficacité de Cabometyx® dans les tumeurs neuroendocrines avancées Regulatory Filings	2024-09-16	French
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis Legal Proceedings Report	2024-09-15	English
Ipsen communique de nouvelles données sur l’essai de Phase III CONTACT-02 dans le cancer de la prostate métastatique résistant à la castration au terme de l’analyse finale de la survie globale Regulatory Filings	2024-09-15	French
Ipsen - Août 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-09-04	French
Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Declaration of Voting Results & Voting Rights Announcements	2024-09-04	English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 32 - 2024 Transaction in Own Shares	2024-08-13	French
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024 Transaction in Own Shares	2024-08-13	English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 31 - 2024 Transaction in Own Shares	2024-08-06	French
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024 Transaction in Own Shares	2024-08-06	English
Ipsen - Juillet 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-08-05	French
Ipsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Declaration of Voting Results & Voting Rights Announcements	2024-08-05	English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 30 - 2024 Transaction in Own Shares	2024-07-30	French
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024 Transaction in Own Shares	2024-07-30	English
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) Interim / Quarterly Report H2 2024	2024-07-25	English
Ipsen S.A.publie son Rapport financier semestriel 2024 (semestre clos le 30 juin 2024) Interim / Quarterly Report H1 2024	2024-07-25	French
Ipsen publie de solides résultats pour le premier semestre 2024, progresse sur ses lancements et revoit à la hausse ses objectifs pour l’exercice en cours Earnings Release H1 2024	2024-07-25	French
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance Earnings Release H1 2024	2024-07-25	English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 29 - 2024 Director's Dealing	2024-07-23	French
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024 Transaction in Own Shares	2024-07-23	English
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024 Director's Dealing	2024-07-16	English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 28 - 2024 Transaction in Own Shares	2024-07-16	French
Ipsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Declaration of Voting Results & Voting Rights Announcements	2024-07-09	English
IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024 Director's Dealing	2024-07-09	English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 27 - 2024 Transaction in Own Shares	2024-07-09	French
Ipsen - Juin 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-07-09	French
Bilan semestriel du contrat de liquidité d'IPSEN - 2024 06 30 Transaction in Own Shares	2024-07-08	French
Half-year statement of IPSEN liquidity agreement - 2024 06 30 Capital/Financing Update	2024-07-08	English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 26 - 2024 Transaction in Own Shares	2024-07-02	French
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024 Transaction in Own Shares	2024-07-02	English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2024 Director's Dealing	2024-06-25	French
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024 Transaction in Own Shares	2024-06-25	English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 24 - 2024 Director's Dealing	2024-06-18	French
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024 Transaction in Own Shares	2024-06-18	English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 23 - 2024 Transaction in Own Shares	2024-06-11	French
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024 Director's Dealing	2024-06-11	English
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-06-06	French
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital Declaration of Voting Results & Voting Rights Announcements	2024-06-06	English
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan Transaction in Own Shares	2024-06-03	English
Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés Transaction in Own Shares	2024-06-03	French
Ipsen annonce le lancement d'une opération d’actionnariat salarié Share Issue/Capital Change	2024-05-30	French
Ipsen announces the launch of an employee shareholding plan Share Issue/Capital Change	2024-05-30	English
Assemblée Générale Annuelle d’Ipsen S.A. du 28 mai 2024 AGM Information	2024-05-28	French
Annual General Meeting of Ipsen S.A. held on 28 May 2024 AGM Information	2024-05-28	English
Descriptif du cadre réglementaire du programme de rachat d’actions soumis par le Conseil d’administration à l’approbation de l’Assemblée Générale Annuelle des actionnaires d’Ipsen S.A. du 28 mai 2024 Transaction in Own Shares	2024-05-28	French
Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024 Transaction in Own Shares	2024-05-28	English
IPSEN SA. - Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée Générale Mixte du 28 mai 2024 AGM Information	2024-05-07	French
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting AGM Information	2024-05-07	English
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-05-06	French
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital Declaration of Voting Results & Voting Rights Announcements	2024-05-06	English
Ipsen appoints Keira Driansky as EVP, President of North America Board/Management Information	2024-05-02	English
Ipsen nomme Keira Driansky, en qualité de Vice-Présidente Exécutive, et Présidente Amérique du Nord Board/Management Information	2024-05-02	French
Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024 Earnings Release Q1 2024	2024-04-24	French
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance Earnings Release Q1 2024	2024-04-24	English
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Regulatory Filings	2024-04-22	French
Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de collaboration de recherche visant le ciblage d’ARN dans les maladies neurologiques rares Regulatory Filings	2024-04-22	French
Ipsen publie son Document d’enregistrement universel 2023 Audit Report / Information FY 2023	2024-04-17	French
Ipsen publishes its 2023 Universal Registration Document Report Publication Announcement	2024-04-17	English
Document d'enregistrement universel 2023 Annual Report (ESEF) FY 2023	2024-04-17	French
Document d'enregistrement universel 2023 Annual Report (ESEF) FY 2023	2024-04-17	French
Franchissement de seuil Major Shareholding Notification	2024-04-15	French
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital Declaration of Voting Results & Voting Rights Announcements	2024-04-08	English
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-04-08	French
Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides Regulatory Filings	2024-04-02	French
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors M&A Activity	2024-04-02	English
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital Regulatory Filings	2024-03-07	English
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Share Issue/Capital Change	2024-03-07	French
Ipsen S.A. publie ses comptes consolidés 2023 Audit Report / Information FY 2023	2024-02-15	French
Ipsen S.A. publishes its 2023 Consolidated Financial Statements Audit Report / Information FY 2023	2024-02-15	English
Ipsen reçoit l’approbation de la FDA pour le schéma thérapeutique incluant Onivyde®, un potentiel nouveau traitement de référence en première ligne dans l'adénocarcinome du pancréas métastatique Regulatory Filings	2024-02-13	French
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA Regulatory Filings	2024-02-13	English
Après de solides résultats pour l’année 2023, Ipsen anticipe quatre lancements commerciaux en 2024. Earnings Release FY 2023	2024-02-08	French
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024 Earnings Release FY 2023	2024-02-08	English
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Declaration of Voting Results & Voting Rights Announcements	2024-02-06	French
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital Declaration of Voting Results & Voting Rights Announcements	2024-02-06	English
Ipsen présente les dernières données d'un essai de Phase III évaluant Cabometyx® en association avec une immunothérapie à l'occasion de l'édition 2024 de l'ASCO sur les cancers génito-urinaires Earnings Release FY 2024	2024-01-22	French
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024 Regulatory Filings	2024-01-22	English
Ipsen – Half year statement – 2023 12 31 Regulatory Filings	2024-01-08	English
Ipsen – Bilan semestriel – 2023 12 31 Regulatory Filings	2024-01-08	French
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Share Issue/Capital Change	2024-01-05	French
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital Declaration of Voting Results & Voting Rights Announcements	2024-01-05	English

Filings by year

2026 32 filings
2025 121 filings
2024 91 filings
2023 157 filings
2022 113 filings
2021 114 filings
2020 97 filings
2019 100 filings
2018 68 filings
2017 115 filings
2016 114 filings
2015 114 filings
2014 98 filings
2013 44 filings